CMIC becomes Align Clinical CRO member to enhance trial partnerships
Category: #health  By Mateen Dalal  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

CMIC becomes Align Clinical CRO member to enhance trial partnerships

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies

CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently announced that it has joined Align Clinical CRO, an industry standards group for life sciences aimed at creating open tech standards that make it easier for CROs and sponsors to work together during trials.

Apparently, CMIC brings over 25 years of experience as a solution provider and operational expertise in clinical trial in Asia and is the first CRO from Japan to join the group. CMIC is teaming up with major CROs partners for the improvement of collaboration and execution during clinical studies.

CMIC is known as a strategic partner that helps sponsors in the rapid development of better medicines with solutions ranging from the development of drug to manufacturing, along with filing to post marketing surveillance.

CMIC HOLDINGS Co., Ltd.’s COO and President Keiko Oishi said that global healthcare sector  is witnessing a significant change. There is an increase in the number of global trials, the study designs are more complex, and the qualification requirements and the kind of service requests are changing as well. Being the member of Align Clinical CRO, the company is committed towards helping the industry increase productivity, run clinical trials efficiently and reduce the operational costs.

For the uninitiated, CMIC started business as the first CRO in Japan in 1992 and today, it provides comprehensive support services for the development of pharmaceutical products, manufacturing and sales and marketing of those products. The company also manages the healthcare business sector and develops as well as sells diagnostic orphan and pharmaceutical drugs, responding to the diversifying needs.

Based on CMIC Group’s accumulated knowledge and experience as a CRO pioneer, the company has developed a business model which is called Pharmaceutical Value Creator (PVC). The PVC is used by the company to create new value in the field of healthcare.

Source Credit- https://www.cmicgroup.com/e/news/20190710

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
By Mateen Dalal

Nuclear Battery Market size will witness growth on account of increasing demand for efficient power generation technologies coupled with improved operational efficiency. Ability of these batteries to generate power in diverse voltage levels based on ...

MediciNova confirms Phase 3 trial of ibudilast in progressive MS
MediciNova confirms Phase 3 trial of ibudilast in progressive MS
By Mateen Dalal

Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics and is traded on Tokyo Stock Exchange’s JASDAQ Market and on NASDAQ Global Mark...

Taku Gold acquires high-grade Portland Gold Project in Yukon
Taku Gold acquires high-grade Portland Gold Project in Yukon
By Mateen Dalal

The acquisition will support Taku’s strategy to capitalize on high-value exploration prospects within the White Gold District. Canada’s gold exploration and resource company, Taku Gold Corp. has recently announced its acquisiti...